Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study

NCT01359228 is registered in ClinicalTrials.gov with University of California, San Francisco as lead sponsor.

NCT NCT01359228
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01359228 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Rifaximin Treatment of Papulopustular Rosacea: Double- Blinded, Placebo-Controlled, Crossover Study
Lead sponsor
University of California, San Francisco
Phase
Phase 2
Overall status
Withdrawn
Start date
April 30, 2013
Completion date
December 31, 2014
Enrollment
0 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

rosacea